Drucker J
Laboratoire de Santé publique, Faculté de Médecine, Tours, France.
Bull Soc Pathol Exot. 1991;84(5 Pt 5):866-72.
A new inactivated poliovirus vaccine of enhanced potency (N-IPV) has been developed since the late 70's. N-IPV can be produced on a large scale in industrial tanks. N-IPV has been extensively studied on all continents and under different climates, specially in tropical countries. It is presently included in vaccination programs of several african regions. N-IPV is recommended in infants as soon as 6 to 8 weeks of age, following a schedule including a primary vaccination with 2 doses at 2 months interval. N-IPV is usually combined to DPT in a quadruple form (DPTPolio). The characteristics and performances of N-IPV make it a substitute or a complement to oral poliovirus vaccine for use in the Expanded Program on Immunization, specially in the perspective of the goal of global poliovirus eradication.
自70年代末以来，已研发出一种效力增强的新型灭活脊髓灰质炎病毒疫苗（N-IPV）。N-IPV可在工业罐体中大规模生产。N-IPV已在各大洲以及不同气候条件下，特别是在热带国家进行了广泛研究。目前它已被纳入几个非洲地区的疫苗接种计划。N-IPV建议在婴儿6至8周龄时尽早接种，按照包括在2个月间隔内接种2剂的初种程序进行。N-IPV通常与白百破疫苗以四联形式（DPTPolio）联合使用。N-IPV的特性和性能使其成为扩大免疫规划中口服脊髓灰质炎病毒疫苗的替代品或补充剂，特别是从全球根除脊髓灰质炎病毒目标的角度来看。
